EU/3/01/023

Table of contents

About

Please note that this product was withdrawn from the Community register of designated orphan medicinal products in November 2012 at the end of the period of market exclusivity.

On 14 February 2001, orphan designation EU/3/01/023 was granted by the European Commission to Pharmacia & Upjohn, United Kingdom, for pegvisomant for the treatment of acromegaly.

Pegvisomant has been authorised in the EU as Somavert since 13 November 2002.

The sponsorhip was transferred to Pharmacia Enterprises SA, Luxembourg, in October 2001 and subsequently to Pfizer Limited, United Kingdom, in November 2003.

Key facts

Active substance
Pegvisomant
Medicine name
Somavert
Disease / condition
Treatment of acromegaly
Date of first decision
15/02/2001
Outcome
Expired
EU designation number
EU/3/01/023

Sponsor's contact details

Pfizer Limited
Ramsgate Road
Sandwich
Kent
CT13 9NJ
United Kingdom
Tel. +44 (0)1304 616161
Fax +44 (0)1304 652144

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating